IL290593A - Related compounds and methods for ablation of m2 macrophages and myeloid-derived suppressor cells - Google Patents

Related compounds and methods for ablation of m2 macrophages and myeloid-derived suppressor cells

Info

Publication number
IL290593A
IL290593A IL290593A IL29059322A IL290593A IL 290593 A IL290593 A IL 290593A IL 290593 A IL290593 A IL 290593A IL 29059322 A IL29059322 A IL 29059322A IL 290593 A IL290593 A IL 290593A
Authority
IL
Israel
Prior art keywords
macrophages
ablation
compositions
related methods
suppressor cells
Prior art date
Application number
IL290593A
Other languages
English (en)
Hebrew (he)
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of IL290593A publication Critical patent/IL290593A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL290593A 2019-08-19 2022-02-13 Related compounds and methods for ablation of m2 macrophages and myeloid-derived suppressor cells IL290593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962888727P 2019-08-19 2019-08-19
PCT/US2020/047036 WO2021034953A1 (en) 2019-08-19 2020-08-19 Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells

Publications (1)

Publication Number Publication Date
IL290593A true IL290593A (en) 2022-04-01

Family

ID=74647058

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290593A IL290593A (en) 2019-08-19 2022-02-13 Related compounds and methods for ablation of m2 macrophages and myeloid-derived suppressor cells

Country Status (7)

Country Link
US (1) US20210052639A1 (https=)
EP (1) EP4017546A4 (https=)
JP (1) JP2022544836A (https=)
CN (1) CN114555131A (https=)
CA (1) CA3151519A1 (https=)
IL (1) IL290593A (https=)
WO (1) WO2021034953A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
WO2025096664A1 (en) * 2023-10-31 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional cd206-binding molecules and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178838B1 (en) * 1999-05-14 2004-09-29 The Regents of the University of California Macromolecular carrier based on dextran for drug and diagnostic agent delivery
AU2006204045B2 (en) * 2005-01-05 2010-10-14 Board Of Regents, The University Of Texas System Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
JP5320569B2 (ja) * 2008-06-28 2013-10-23 公益財団法人神奈川科学技術アカデミー 高分子ミセル及びそれを有効成分として含有する固形がんの診断又は治療剤
CN114377143A (zh) * 2013-07-22 2022-04-22 康德乐健康414有限责任公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
EP3522899A4 (en) * 2016-10-07 2020-05-06 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1

Also Published As

Publication number Publication date
EP4017546A4 (en) 2023-09-27
JP2022544836A (ja) 2022-10-21
WO2021034953A1 (en) 2021-02-25
EP4017546A1 (en) 2022-06-29
US20210052639A1 (en) 2021-02-25
CA3151519A1 (en) 2021-02-25
CN114555131A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
IL290593A (en) Related compounds and methods for ablation of m2 macrophages and myeloid-derived suppressor cells
SG11202100533VA (en) Hepato-biliary-pancreatic tissues and methods of making same
ZA202006610B (en) Compositions for the treatment of skin conditions
GB201919131D0 (en) Combining of spatial audio parameters
ZA202007055B (en) Compositions for the treatment of skin conditions
IL288510A (en) Anti-psgl-1 preparations and methods for modulating inflammatory myeloid cell phenotypes and uses thereof
IL288511A (en) Anti-siglec-9 preparations and methods for modulating inflammatory myeloid cell phenotypes and uses thereof
IL276135A (en) Preparations and methods of use
IL292773A (en) Preparations and methods for activating integrins
GB202017593D0 (en) Compositions and methods and uses relating thereto
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL289687A (en) Preparations for the treatment of hair loss
IL287797A (en) Oligosaccharide preparations and methods of use
IL286678A (en) Preparations and methods for changing macrophage phenotype
EP3847437A4 (en) Compositions and methods for the assessment of soil quality
EP3544420B8 (en) Use of compositions for organ/tissue preservation
IL291336A (en) Methods and preparations for tissue regeneration
IL290325A (en) Biopharmaceutical preparations and related methods
IL290324A (en) Preparations containing tropintide
IL286587A (en) Preparations of d-methyrosine and methods for their preparation
SG11202111081XA (en) Compositions and methods for the cryopreservation of immune cells
IL278972B (en) Methods and compositions comprising bucindolol for the treatment of atrial fibrillation
IL290966A (en) Allogeneic cell preparations and methods of use
IL289166A (en) Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use
HK40075093A (en) Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells